The Company was restructured into a stock company from Shandong Reeking Pharmaceutical Distribution Co., Ltd. initiated by Miss Zhang Renhua, Mr. Han Xu, TBNatureLimited and Qingdao Ruihua Pharmaceutical Strategy Consulting Services Ltd. The company is a high-growth, medium-sized pharmaceutical direct marketing services provider, with Shandong Province as its target market. It main business is direct marketing to large-scale hospitals and basic health care market which is complemented by commercial distribution. It is a pharmaceutical business enterprise with modern pharmaceutical logistics qualification and ability and modern means of management such as e-commerce.
Basic Information
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Director
Purchase this report to view the information.
General Manager
Purchase this report to view the information.
Deputy General Manager
Ownership Details
Purchase this report to view the information.
17.08%
Purchase this report to view the information.
12.46%
Purchase this report to view the information.
5%
Purchase this report to view the information.
1.97%
Purchase this report to view the information.
1.78%
Subsidiaries
Anhui Ceyue Medical Technology Co., Ltd.
100%
Anhui Jingquan Chinese Medicinal Plants Co., Ltd.
100%
Auspicious Ze (Yantai) Medical Equipment Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Realcan Pharmaceutical Group Co., Ltd. report is purchased.
Looking for more than just a company report?
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-38.21%▼
Total operating revenue
-37.81%▼
Operating profit (EBIT)
-64.46%▼
Net Profit (Loss) for the Period
-62.67%▼
Operating Profit Margin (ROS)
-1.33%▼
Net Profit Margin
-0.88%▼
Return on Equity (ROE)
-2.17%▼
Debt to Equity Ratio
-5.07%▼